Hepatic impairment

The liver metabolizes most drugs via cytochrome P450 enzymes and conjugation pathways, and synthesizes albumin, which binds many compounds in the bloodstream. Hepatic impairment refers to any meaningful reduction in this capacity — from chronic diseases such as cirrhosis or viral hepatitis, acute liver injury, or age-related functional decline.

When clearance is impaired, a compound and its metabolites remain active in the body longer than standard dosing assumes. This is distinct from hepatotoxicity, which refers to damage a substance actively causes to liver tissue. Hepatic impairment is a modifier of exposure; hepatotoxicity is a mechanism of harm.

How it works · its role

The liver processes substances in two stages. Phase I reactions — primarily oxidation by cytochrome P450 enzymes — convert parent compounds into metabolites. Phase II reactions then conjugate those metabolites into water-soluble forms the kidneys can excrete.

Hepatic impairment degrades both stages. CYP enzyme activity falls. In severe disease, increased resistance in the hepatic portal circulation reduces how much blood the liver processes per pass. For substances with high first-pass extraction — those that ordinarily lose most of their absorbed dose before reaching systemic circulation — this failure can sharply raise plasma concentrations after oral dosing.

Reduced albumin synthesis compounds the effect. Because albumin binds many drugs in the bloodstream, lower levels shift more drug into its free, pharmacologically active form — an additive amplifier on top of slower clearance.

Relevance to substances & effects

Opioids — morphine, oxycodone, fentanyl — undergo extensive metabolism; in impaired individuals both the parent drug and active metabolites can accumulate beyond expected levels. Benzodiazepines with long-lived active metabolites, such as diazepam, are particularly vulnerable to this kind of stacking.

Many sedative-hypnotics, antidepressants, and cannabis-derived compounds are similarly eliminated by the liver, placing them in the same risk category.

Alcohol occupies a distinct position: the liver is its primary clearance route via alcohol dehydrogenase, and impaired hepatic function both slows ethanol elimination and leaves the liver more susceptible to further damage — the two effects reinforce each other.

Prodrugs requiring hepatic activation — codeine, for instance, which depends on CYP2D6 to convert to morphine — may show reduced efficacy in impaired individuals alongside slower clearance of whatever active compound is formed.

Clinical · risk note

Hepatic impairment is graded — mild, moderate, and severe — using clinical scoring systems that weigh bilirubin, albumin, clotting function, and other markers. Contraindication listings on substance pages typically specify the grade at which caution or avoidance applies, because mild impairment may have modest pharmacokinetic consequences while severe cirrhosis can multiply effective exposure severalfold.

For substances with narrow therapeutic windows — sedatives, opioids, and anticoagulants among them — impaired clearance means standard doses can behave as relative overdoses. This is why hepatic status appears as a recurring variable in the safety layer, not a one-off footnote.